North China Pharmaceutical Co Ltd

North China Pharmaceutical announced that its wholly-owned subsidiary Southern Company has received the supplementary application approval notice for injectable lysine acetylsalicylate issued by the National Medical Products Administration. The 0.9g strength passed the generic drug quality and efficacy consistency evaluation, while the 1.8g strength is a newly added specification, for which a drug approval number was issued and it is deemed to have passed the consistency evaluation. Lysine acetylsalicylate is a non-steroidal anti-inflammatory drug that breaks down into lysine and aspirin in the body, providing antipyretic, analgesic, anti-inflammatory, and antiplatelet aggregation effects. It is suitable for the treatment of fever and mild to moderate pain in patients for whom oral administration is not appropriate.

North China Pharmaceutical announced that the company and its subsidiaries Huamin Company and Nanfang Company have a total of eight drugs tentatively selected for the 12th National Centralized Drug Procurement organized by the state. The tentatively selected products include ciclosporin soft capsules and tacrolimus capsules, with a public notice period from July 31 to August 5, 2026. In the first quarter of 2026, North China Pharmaceutical achieved revenue of 2.153 billion yuan and net profit attributable to the parent company of 35.47 million yuan.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.